Yahoo
    NYSE - Delayed Quote USD

    Organon & Co. (OGN)

    13.78 +0.01 (+0.07%)
    At close: September 4 at 4:00:02 PM EDT
    13.77 -0.01 (-0.07%)
    After hours: September 4 at 7:30:07 PM EDT
    Trade OGN on Coinbase
    Loading Chart for OGN
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Orogen Royalties Acquires Two Gold Projects in Southwest Utah

    Orogen Royalties Acquires Two Gold Projects in Southwest Utah
    ACCESS Newswire 4d ago
    Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer

    Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer
    GlobeNewswire 5d ago
    Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

    Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
    Zacks 1mo ago
    Organon & Co. Shareholders Clear Sun Pharma Merger Deal

    Organon & Co. Shareholders Clear Sun Pharma Merger Deal
    MarketBeat 1mo ago
    Organon (OGN) Names A Canada Chief, Is The Stock Cheap?

    Organon (OGN) Names A Canada Chief, Is The Stock Cheap?
    Simply Wall St. 1mo ago
    Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

    Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
    Business Wire 1mo ago
    Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

    Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
    Zacks 1mo ago
    Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

    Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
    Business Wire 2mo ago
    Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

    Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
    Business Wire 2mo ago
    Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?

    Can Organon & Co. (OGN)’s MIUDELLA Launch Become a Major Driver in Women’s Health Markets?
    Insider Monkey 2mo ago
    Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

    Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
    Motley Fool 5mo ago

    Related Tickers

    MRK
    BMY
    GSK
    SNY
    BIIB
    AZN
    NVS
    AMGN
    GILD
    PFE
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: